Dose escalation model for limited-stage small-cell lung cancer.
OBJECTIVE
To construct a model for the local dose-response relationship of limited-stage small-cell lung cancer (LS-SCLC) along with subsequent models for dose-per-fraction escalation.


METHODS
Reported doses and 2-year progression free survival (PFS(2year)) rates from LS-SCLC studies were used to construct a dose-response model. Modeling incorporated effects of chemotherapy, incomplete repair of sublethal damage and variations in both kick-off time for rapid reproliferation and effective tumor cell doubling time. Response was modeled as a function of overall treatment duration in order to shed light on the optimum radiotherapy treatment duration. Subsequent models were constructed for more aggressive radiotherapy by means of dose-per-fraction escalation for once a day (QD) and twice a day (BID) fractionation schedules.


RESULTS
Modeling response as a function of treatment duration resulted in an optimum treatment duration of 3 weeks for both fractionation schedules. Modeling for dose-per-fraction escalation resulted in an increase in the expected local PFS(2year) for both fractionation schedules with possible gains in a BID schedule with lower expected late complication rates than a QD schedule yielding the same expected local PFS(2year).


CONCLUSIONS
This modeling suggests more aggressive treatment through escalation of dose-per-fraction, which may result in substantial gains in local PFS(2year). This points towards treatment durations of 3 weeks as being optimal with a BID schedule predicting possible gains in local PFS(2year) at lower rates of expected late complications than a QD schedule.
Arvidson
Noah B
NB
Department of Medical Physics, University of Wisconsin, Madison, WI 53792, USA.
Khuntia
Deepak
D
Tomé
Wolfgang A
WA
D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018450:Disease Progression; D019583:Dose Fractionation, Radiation; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D015233:Models, Statistical; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents